CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, CVS Health (CVS) closed at $74.81, marking a -1.36% move from the previous day. This change lagged the S&P 500's 0.25% gain on the day. Meanwhile, the Dow experienced a rise of 0.1%, and the technology-dominated Nasdaq saw an increase of 0.47%. Shares of the drugstore chain and pharmacy benefits manager have depreciated by 3.36% over the course of the past month, outperforming the Medical sector's loss of 4.79%, and lagging the S&P 500's loss of 1.88%.The investment community will be paying close attention to the earnings performance of CVS Health in its upcoming release. The company is predicted to post an EPS of $2.22, indicating a 1.33% decline compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $95.2 billion, indicating a 0.65% growth compared to the corresponding quarter of the prior year. CVS's full-year Zacks Consensus Estimates are calling for earnings of $7.15 per share and revenue of $407.48 billion. These results would represent year-over-year changes of +5.93% and +1.35%, respectively. Investors should also take note of any recent adjustments to analyst estimates for CVS Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.12% lower. Right now, CVS Health possesses a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that CVS Health has a Forward P/E ratio of 10.6 right now. This represents a discount compared to its industry average Forward P/E of 15.12. It's also important to note that CVS currently trades at a PEG ratio of 0.79. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Services was holding an average PEG ratio of 1.44 at yesterday's closing price. The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 140, putting it in the bottom 43% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.See Our Newest 5 Stocks Set to Double Picks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks